NanoPacific Holdings (NPH) obtained an exclusive, worldwide license from University of California at Los Angeles (UCLA) for a suite of supramolecular nanoparticle technologies. The technology has implications for drug delivery, gene transfection centering on siRNA, and companion diagnostics.

The system is composed of a ternary mixture of modular components that self-assemble into supramolecular nanoparticles. It enables the synthesis of new-generation nanoparticles with a high degree of size and morphological control as well as tunable surface charge and chemistry, according to NPH and UCLA. These properties enable the production of biodegradable nanoparticles that display improved physiological stability, longer blood retention times, low acute toxicity, and low immunogenicity, they continue. The tunable surface properties allow several types of functionality to be incorporated for imaging (optical, magnetic, and nuclear), targeting, and controlled delivery of cargo.

Previous articleResearchers Awarded $2.4M to Study Neuronal Regeneration
Next articleYM Biosciences Claims Collaboration with Canada’s NRC-BRI Yielded Novel Anticancer Antibodies